Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia

Hematology/Oncology Clinics of North America

Volumn 29, Issue 3, 2015, Pages 455-471

  Berentsen, Sigbjørn ^a   Randen, Ulla ^b   Tjønnfjord, Geir E ^b  

^a HAUGESUND HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Autoimmune hemolytic anemia; B lymphocytes; Cold agglutinin; Cold agglutinin disease; Cold agglutinin syndrome; Complement; Lymphoproliferative disorders; Therapy

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AZATHIOPRINE; BENDAMUSTINE; BORTEZOMIB; CD59 ANTIGEN; CLADRIBINE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COLD AGGLUTININ; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DECAY ACCELERATING FACTOR; ERYTHROPOIETIN; FLUDARABINE; HEMOGLOBIN; RITUXIMAB; COMPLEMENT; CRYOGLOBULIN;

ACROCYANOSIS; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CLONAL VARIATION; COMBINATION CHEMOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COOMBS TEST; CRYOPROTECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; HEMOGLOBINURIA; HEPATITIS B; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTRAVASCULAR HEMOLYSIS; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOPLASMOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONSET AGE; OVERALL SURVIVAL; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTECTIVE CLOTHING; RAYNAUD PHENOMENON; REVIEW; SEX RATIO; B LYMPHOCYTE; BIOLOGICAL MODEL; COMPLEMENT CLASSICAL PATHWAY; HEMOLYSIS; IMMUNOLOGY;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; B-LYMPHOCYTES; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; CRYOGLOBULINS; HEMOLYSIS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MODELS, IMMUNOLOGICAL;

EID: 84930044052     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.01.002     Document Type: Review

References (84)

1. Sokol R.J., Hewitt S., Stamps B.K. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed) 1981, 282(6281):2023-2027.
2. Dacie J. The auto-immune haemolytic anaemias: introduction. The haemolytic anaemias 1992, vol. 3:1-5. Churchill Livingstone, London.
3. Berentsen S., Tjonnfjord G.E. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 2012, 26(3):107-115.
4. Landsteiner K. Über Beziehungen zwischen dem Blutserum und den Körperzellen. Münch Med Wschr 1903, 50:1812-1814.
5. Ulvestad E., Berentsen S., Bo K., et al. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol 1999, 63(4):259-266.
6. Jain M.D., Cabrerzio-Sanchez R., Karkouti K., et al. Seek and you shall find-but then what do you do? Cold agglutinins in cardiopulmonary bypass and a single-center experience with cold agglutinin screening before cardiac surgery. Transfus Med Rev 2013, 27(2):65-73.
7. Bendix B.J., Tauscher C.D., Bryant S.J., et al. Defining a reference range for cold agglutinin titers. Transfusion 2014, 54(5):1294-1297.
8. Dacie J. Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes II: immunochemistry and specificity of the antibodies; serum complement in auto-immune haemolytic anaemia. The haemolytic anaemias 1992, vol. 3:240-295. Churchill Livingstone, London.
9. Stone M.J., McElroy Y.G., Pestronk A., et al. Human monoclonal macroglobulins with antibody activity. Semin Oncol 2003, 30(2):318-324.
10. Hopkins C., Walters T.K. Thermal amplitude test. Immunohematology 2013, 29(2):49-50.
11. Garratty G., Petz L.D., Hoops J.K. The correlation of cold agglutinin titrations in saline and albumin with haemolytic anaemia. Br J Haematol 1977, 35(4):587-595.
12. Rosse W.F., Adams J.P. The variability of hemolysis in the cold agglutinin syndrome. Blood 1980, 56(3):409-416.
13. Berentsen S., Bo K., Shammas F.V., et al. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS 1997, 105(5):354-362.
14. Bhattacharyya J., Mihara K., Takihara Y., et al. Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide. Ann Hematol 2012, 91(5):797-799.
15. Issitt P.D. Iblood group system and its relationship to disease. JMed Lab Technol 1968, 25(1):1-6.
16. Marsh W.L. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haematol 1961, 7:200-209.
17. Silberstein L.E., Robertson G.A., Harris A.C., et al. Etiologic aspects of cold agglutinin disease: evidence for cytogenetically defined clones of lymphoid cells and the demonstration that an anti-Pr cold autoantibody is derived from a chromosomally aberrant B cell clone. Blood 1986, 67(6):1705-1709.
18. Brain M.C., Ruether B., Valentine K., et al. Life-threatening hemolytic anemia due to an autoanti-Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination. Transfusion 2010, 50(2):292-301.
19. Harboe M., Deverill J. Immunochemical properties of cold haemagglutinins. Scand J Haematol 1964, 61:223-237.
20. Hughey C.T., Brewer J.W., Colosia A.D., et al. Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. JImmunol 1998, 161(8):4091-4097.
21. Berentsen S., Ulvestad E., Langholm R., et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006, 91(4):460-466.
22. Randen U., Troen G., Tierens A., et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 2014, 99(3):497-504.
23. Christenson W.N., Dacie J.V., Croucher B.E., et al. Electrophoretic studies on sera containing high-titre cold haemagglutinins: identification of the antibody as the cause of an abnormal gamma 1 peak. Br J Haematol 1957, 3(3):262-275.
24. Harboe M., van Furth R., Schubothe H., et al. Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol 1965, 2(3):259-266.
25. Schubothe H. The cold hemagglutinin disease. Semin Hematol 1966, 3(1):27-47.
26. Pascual V., Victor K., Spellerberg M., et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. JImmunol 1992, 149(7):2337-2344.
27. Swiecicki P.L., Hegerova L.T., Gertz M.A. Cold agglutinin disease. Blood 2013, 122(7):1114-1121.
28. Treon S.P., Xu L., Yang G., et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. NEngl J Med 2012, 367(9):826-833.
29. Xu L., Hunter Z.R., Yang G., et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013, 121(11):2051-2058.
30. Shi J., Rose E.L., Singh A., et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies. Blood 2014, 123(26):4015-4022.
31. Jonsen J., Kass E., Harboe M. Complement and complement components in acquired hemolytic anemia with high titer cold antibodies. Acta Med Scand 1961, 170:725-729.
32. Jaffe C.J., Atkinson J.P., Frank M.M. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. JClin Invest 1976, 58(4):942-949.
33. Kurlander R.J., Rosse W.F., Logue G.L. Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis. JClin Invest 1978, 61(5):1309-1319.
34. Roth A., Huttmann A., Rother R.P., et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009, 113(16):3885-3886.
35. Lyckholm L.J., Edmond M.B. Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome. NEngl J Med 1996, 334(7):437.
36. Ulvestad E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol 1998, 60(2):93-100.
37. Ulvestad E., Berentsen S., Mollnes T.E. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol 2001, 54(1-2):239-242.
38. Berentsen S., Beiske K., Tjonnfjord G.E. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology 2007, 12(5):361-370.
39. Dacie J. Treatment and prognosis of cold-antibody AIHA. The haemolytic anaemias 1992, vol. 3:502-508. Churchill Livingstone, London.
40. Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011, 153(3):309-317.
41. Nydegger U.E., Kazatchkine M.D., Miescher P.A. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol 1991, 28(1):66-77.
42. Rosenfield R.E., Jagathambal Transfusion therapy for autoimmune hemolytic anemia. Semin Hematol 1976, 13(4):311-321.
43. Lodi G., Resca D., Reverberi R. Fatal cold agglutinin-induced haemolytic anaemia: a case report. JMed Case Rep 2010, 4:252.
44. Zoppi M., Oppliger R., Althaus U., et al. Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed 1993, 20(1-2):19-22.
45. Silberstein L.E., Berkman E.M., Schreiber A.D. Cold hemagglutinin disease associated with IgG cold-reactive antibody. Ann Intern Med 1987, 106(2):238-242.
46. Gertz M.A. Management of cold haemolytic syndrome. Br J Haematol 2007, 138(4):422-429.
47. Worlledge S.M., Brain M.C., Cooper A.C., et al. Immunosuppressive drugs in the treatment of autoimmune haemolytic anaemia. Proc R Soc Med 1968, 61(12):1312-1315.
48. Hippe E., Jensen K.B., Olesen H., et al. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood 1970, 35(1):68-72.
49. Berentsen S., Tjonnfjord G.E., Shammas F.V., et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol 2000, 65(1):88-90.
50. Hillen H.F., Bakker S.J. Failure of interferon-alpha-2b therapy in chronic cold agglutinin disease. Eur J Haematol 1994, 53(4):242-243.
51. O'Connor B.M., Clifford J.S., Lawrence W.D., et al. Alpha-interferon for severe cold agglutinin disease. Ann Intern Med 1989, 111(3):255-256.
52. Berentsen S., Ulvestad E., Tjonnfjord G.E. B-lymphocytes as targets for therapy in chronic cold agglutinin disease. Cardiovasc Hematol Disord Drug Targets 2007, 7(3):219-227.
53. Stone M.J. Heating up cold agglutinins. Blood 2010, 116(17):3119-3120.
54. Zanella A., Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014, 99(10):1547-1554.
55. Berentsen S., Ulvestad E., Gjertsen B.T., et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004, 103(8):2925-2928.
56. Schollkopf C., Kjeldsen L., Bjerrum O.W., et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006, 47(2):253-260.
57. Ghielmini M., Schmitz S.F., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103(12):4416-4423.
58. Cooper N., Arnold D.M. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010, 149(1):3-13.
59. Berentsen S., Randen U., Vagan A.M., et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 2010, 116(17):3180-3184.
60. Leleu X., Tamburini J., Roccaro A., et al. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma 2009, 9(1):71-73.
61. Gueli A., Gottardi D., Hu H., et al. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. Blood Transfus 2013, 11(2):311-314.
62. Carson K.R., Beckwith L.G., Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010, 115(4):915.
63. Bork K., Steffensen I., Machnig T. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. Allergy Asthma Proc 2013, 34(4):312-327.
64. Wouters D., Stephan F., Strengers P., et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood 2013, 121(7):1242-1244.
65. Panicker S, Shi J, Rose E, etal. TNT009, a classical complement pathway specific inhibitor, prevents complement dependent hemolysis induced by cold agglutinin disease patient autoantibodies. 55th Meeting of the American Society of Hematology. New Orleans (LA), December 08, 2013 (Paper 64043). Available at: https://ash.confex.com/ash/2013/webprogram/Paper64043.html.
66. Berentsen S. Complement, cold agglutinins, and therapy. Blood 2014, 123(26):4010-4012.
67. Larghi E.L., Kaufman T.S. Modulators of complement activation: a patent review (2008-2013). Expert Opin Ther Pat 2014, 24(6):665-686.
68. Sharp J.A., Whitley P.H., Cunnion K.M., et al. Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol 2014, 5:406.
69. Risitano A.M., Ricklin D., Huang Y., et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123(13):2094-2101.
70. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. NEngl J Med 2006, 355(12):1233-1243.
71. Ginsberg H.S. Acute hemolytic anemia in primary atypical pneumonia associated with high titer of cold agglutinins; report of a case. NEngl J Med 1946, 234:826-829.
72. Dacie J. Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes III: haemolytic anaemia following mycoplasma pneumonia. The haemolytic anaemias 1992, vol. 3:296-312. Churchill Livingstone, London.
73. Linz D.H., Tolle S.W., Elliot D.L. Mycoplasma pneumoniae pneumonia. Experience at a referral center. West J Med 1984, 140(6):895-900.
74. Schubothe H., Merz K.P., Weber S., et al. Akute autoimmunhämolytische Anemie vom Kältenantikörpertype mit tödlichem Ausgang. Acta Haematol 1970, 44(1):111-123.
75. Jenkins W.J., Koster H.G., Marsh W.L., et al. Infectious mononucleosis: an unsuspected source of anti-i. Br J Haematol 1965, 11:480-483.
76. Luzuriaga K., Sullivan J.L. Infectious mononucleosis. NEngl J Med 2010, 362(21):1993-2000.
77. Dacie J. Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes IV: haemolytic anaemia following infectious mononucleosis and other viral infections. The haemolytic anaemias 1992, vol. 3:313-328. Churchill Livingstone, London.
78. Berlin B.S., Chandler R., Green D. Anti-"I" antibody and hemolytic anemia associated with spontaneous cytomegalovirus mononucleosis. Am J Clin Pathol 1977, 67(5):459-461.
79. Crisp D., Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982, 72(6):915-922.
80. Niainle F., Hamnvik O.P., Gulmann C., et al. Diffuse large B-cell lymphoma with isolated bone marrow involvement presenting with secondary cold agglutinin disease. Int J Lab Hematol 2008, 30(5):444-445.
81. Dacie J. Haemolytic anaemias associated with malignant lymphomas other than Hodgkin's disease and chronic lymphocytic leukaemia (CLL). The haemolytic anaemias 1995, vol. 4:27-40. Churchill Livingstone, London.
82. Chu C.S., Braun S.R., Yarbro J.W., et al. Corticosteroid treatment of hemolytic anemia associated with Mycoplasma pneumoniae pneumonia. South Med J 1990, 83(9):1106-1108.
83. Tsuruta R., Kawamura Y., Inoue T., et al. Corticosteroid therapy for hemolytic anemia and respiratory failure due to Mycoplasma pneumoniae pneumonia. Intern Med 2002, 41(3):229-232.
84. Geurs F., Ritter K., Mast A., et al. Successful plasmapheresis in corticosteroid-resistant hemolysis in infectious mononucleosis: role of autoantibodies against triosephosphate isomerase. Acta Haematol 1992, 88(2-3):142-146.